The WHO 2019 classification of pancreatic neuroendocrine tumors (PanNETs) introduced a grade 3 category. The distinguishing feature between a WHO Grade 3 PanNET (G3 NET) and a large-cell pancreatic neuroendocrine carcinoma (LCNEC) is:

• A G3 PanNET is treated with platinum-based chemotherapy; LCNEC is treated with somatostatin analogues
• B G3 PanNET is always non-functional; LCNEC is always associated with Zollinger-Ellison syndrome
• C G3 PanNET is well-differentiated with Ki-67 >20% (typically 20–55%) and retained organoid architecture; LCNEC is poorly differentiated with Ki-67 typically >55%, diffuse growth, and common TP53/RB1 mutations ✓
• D G3 PanNET and LCNEC are distinguished only by mitotic rate, not Ki-67 or architectural pattern

Explanation

The 2019 WHO classification of pancreatic tumors separates pancreatic NENs into well-differentiated PanNETs (Grades 1–3 based on Ki-67 and mitotic rate) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs: small cell and large cell types). The critical distinction is morphological differentiation: G3 PanNETs retain organoid architecture (nesting, trabecular, acinar), have uniform nuclei, and have Ki-67 typically 20–55%; they carry DAXX/ATRX and MEN1 mutations like G1/G2 PanNETs and respond to NET-directed therapy including somatostatin analogues and targeted agents. PanNECs (including LCNEC) are poorly differentiated, lose organoid architecture, have diffuse/sheet-like growth, Ki-67 often >55%, and harbor TP53 and RB1 mutations — consistent with neuroendocrine carcinomas requiring platinum-etoposide chemotherapy as in lung SCLC/LCNEC.

Reference: Robbins & Cotran Pathologic Basis of Disease, 10th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.